Article Versions Notes

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, et al. Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers. 2023; 15(4):1299. https://doi.org/10.3390/cancers15041299

Galland, Loïck, Nicolas Roussot, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Manon Reda, Juliette Albuisson, Laurent Arnould, and et al. 2023. "Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer" Cancers 15, no. 4: 1299. https://doi.org/10.3390/cancers15041299

Galland, L., Roussot, N., Desmoulins, I., Mayeur, D., Kaderbhai, C., Ilie, S., Hennequin, A., Reda, M., Albuisson, J., Arnould, L., Boidot, R., Truntzer, C., Ghiringhelli, F., & Ladoire, S. (2023). Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer. Cancers, 15(4), 1299. https://doi.org/10.3390/cancers15041299